Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study

• Francesco Trotta,

  Affiliation Department of Epidemiology, Lazio Regional Health Service, Rome, Italy

  ⨯
• Stefania Spila-Alegiani ,

  * E-mail: stefania.spila@iss.it

  Affiliation Pharmacoepidemiology Unit, National Centre for Epidemiology, National Institute of Health, Rome, Italy

  ⨯
• Roberto Da Cas,

  Affiliation Pharmacoepidemiology Unit, National Centre for Epidemiology, National Institute of Health, Rome, Italy

  ⨯
• Maja Rajevic,

  Affiliation PhD Course, Pharmaceutical Sciences, Drug Chemistry and Technologies Department, “La Sapienza” University of Rome, Rome, Italy

  ⨯
• Valentino Conti,

  Affiliation Regional Center for Pharmacovigilance, General Directorate for Health, The Lombardy Region, Milan, Italy

  ⨯
• Mauro Venegoni,

  Affiliation Regional Center for Pharmacovigilance, General Directorate for Health, The Lombardy Region, Milan, Italy

  ⨯
• Mariangela Rossi,

  Affiliation Unit for Pharmaceutical Governance, General Directorate for Health, Umbria Region, Perugia, Italy

  ⨯
• Giuseppe Traversa

  Affiliation Pharmacoepidemiology Unit, National Centre for Epidemiology, National Institute of Health, Rome, Italy

  ⨯